Tumor-derived annexin A1 drives lenvatinib resistance by regulating SOX2/STAT3/S100A6 feedback loop and M2 macrophage polarization in hepatocellular carcinoma
Open Access
- 29 July 2026
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Abstract
Lenvatinib has been approved by the FDA as a front-line treatment for advanced hepatocellular carcinoma (HCC), but its survival benefits are limited by acquired drug resistance. In this study, we investigate the mechanisms underlying lenvatinib resistance in HCC by establishing lenvatinib-resistant (LenR) patient-derived tumor xenograft (PDTX) and analyzing their genetic profiles via single-cell RNA sequencing (scRNA-seq). Through single-cell regulatory network inference and clustering (SCENIC) analysis, we find that Annexin A1 ( ANXA1 ) is significantly enriched in LenR HCC clusters. Using knockdown and overexpression strategies, we demonstrate the critical role of ANXA1 in regulating cancer stemness-driven lenvatinib resistance. ANXA1 mediates resistance by regulating S100A6 expression, while its expression is regulated by SOX2 via promoter activation, forming a positive feedback loop with STAT3. Notably, we reveal that ANXA1 secreted from LenR HCC cells reshapes the tumor microenvironment (TME) by inducing M2 macrophage polarization via FPR2 binding and activation of ERK and NF-κB signaling, leading to decreased T cell infiltration. Targeting ANXA1 via an adeno-associated virus serotype 8 (AAV8) approach improves lenvatinib efficacy in our LenR Tp53 KO / Myc OE HCC mouse model, accompanied by the suppression of an immunosuppressive TME. In conclusion, HCC-derived ANXA1 regulates lenvatinib resistance both intrinsically and extrinsically. Targeting the SOX2/ANXA1/STAT3/S100A6 positive loop may provide a novel therapeutic strategy for HCC treatment.Keywords
This publication has 33 references indexed in Scilit:
- Increased expression of annexin A1 predicts poor prognosis in human hepatocellular carcinoma and enhances cell malignant phenotypeMedical Oncology, 2014
- Characterization of pro-invasive mechanisms and N-terminal cleavage of ANXA1 in melanomaArchives of Dermatological Research, 2014
- Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinomaJournal of Molecular Medicine, 2013
- Identification of annexin A1 as a proinvasive and prognostic factor for lung adenocarcinomaClinical & Experimental Metastasis, 2011
- Increased Expression of Annexin A1 Is Correlated with K-Ras Mutation in Colorectal CancerThe Tohoku Journal of Experimental Medicine, 2010
- Design and Endpoints of Clinical Trials in Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2008
- Regulation of Sox2 by STAT3 Initiates Commitment to the Neural Precursor Cell FateStem Cells and Development, 2008
- Annexin-I expression modulates drug resistance in tumor cellsBiochemical and Biophysical Research Communications, 2004
- Hydroporation as the mechanism of hydrodynamic deliveryGene Therapy, 2004
- Anti-inflammatory effects of annexin-1: stimulation of IL-10 release and inhibition of nitric oxide synthesisInternational Immunopharmacology, 2003